• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.

作者信息

Ramael M, Van den Bossche J, Buysse C, Deblier I, Segers K, Van Marck E

机构信息

Laboratory of Pathology, University Hospital Antwerp, Edegem, Belgium.

出版信息

Histol Histopathol. 1995 Jul;10(3):639-43.

PMID:7579812
Abstract

We studied immunoreactivity for c-fos protein and c-myc protein in malignant mesothelioma (36 cases) and non-neoplastic pleural mesothelium (45 cases) using the murine monoclonal antibodies 14E10 and 6E10. All malignant mesotheliomas and cases with non-neoplastic mesothelium exhibited not only nuclear but also cytoplasmic immunoreactivity for c-fos and c-myc protein in the majority of mesothelial cells. There was no statistically significant difference between the various mesothelioma subtypes or between neoplastic and non-neoplastic mesothelium for c-fos protein immunoreactivity (p > 0.05). There was statistically significant difference between neoplastic and non-neoplastic mesothelium for c-myc protein immunoreactivity (p < 0.01). We conclude that immunoreactivity for c-fos and c-myc protein is present in both non-neoplastic and neoplastic mesothelium, but that a higher proportion of neoplastic mesothelial cells are immunoreactive for c-myc protein when compared with non-neoplastic mesothelium.

摘要

相似文献

1
Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
Histol Histopathol. 1995 Jul;10(3):639-43.
2
Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1.
J Pathol. 1992 May;167(1):5-8. doi: 10.1002/path.1711670103.
3
Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.恶性间皮瘤和非肿瘤性间皮中p53蛋白的免疫反应性。
J Pathol. 1992 Dec;168(4):371-5. doi: 10.1002/path.1711680406.
4
Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
J Pathol. 1992 May;167(1):1-4. doi: 10.1002/path.1711670102.
5
Immunohistochemical staining of ras oncogene product in neoplastic and non-neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras.肿瘤性和非肿瘤性间皮组织中ras癌基因产物的免疫组织化学染色:N-ras免疫反应性以及Ha-ras和K-ras免疫组织化学染色阴性。
J Pathol. 1993 Apr;169(4):421-4. doi: 10.1002/path.1711690406.
6
WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.恶性间皮瘤中的WT1突变以及与p53、生长因子受体表达、细胞类型转变和预后相关的WT1免疫反应性。
J Pathol. 1997 Jan;181(1):67-74. doi: 10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z.
7
Differential immunohistochemical staining for retinoblastoma protein with the antibodies C15 and 1F8 in malignant mesothelioma.在恶性间皮瘤中使用C15和1F8抗体对视网膜母细胞瘤蛋白进行差异免疫组化染色。
Pathol Res Pract. 1994 Feb;190(2):138-41. doi: 10.1016/S0344-0338(11)80703-X.
8
Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.恶性间皮瘤和非肿瘤性间皮中表皮生长因子受体的免疫组织化学分布模式
Virchows Arch A Pathol Anat Histopathol. 1991;419(3):171-5. doi: 10.1007/BF01626344.
9
c-Kit is not expressed in malignant mesothelioma.
Mod Pathol. 2003 Aug;16(8):818-22. doi: 10.1097/01.MP.0000083647.69123.5C.
10
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA).
J Pathol. 1994 Mar;172(3):247-53. doi: 10.1002/path.1711720304.

引用本文的文献

1
Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma.生长激素释放激素拮抗剂增强培美曲塞和顺铂治疗胸膜间皮瘤的抗肿瘤作用。
Int J Mol Sci. 2022 Sep 24;23(19):11248. doi: 10.3390/ijms231911248.
2
Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.靶向MYC可使恶性间皮瘤细胞对PAK阻断诱导的细胞毒性敏感。
Am J Cancer Res. 2017 Aug 1;7(8):1724-1737. eCollection 2017.
3
CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways.
CELLFOOD™通过调节p53、c-myc和pAkt信号通路诱导人恶性间皮瘤和结肠直肠癌细胞凋亡。
J Exp Clin Cancer Res. 2014 Mar 5;33(1):24. doi: 10.1186/1756-9966-33-24.
4
Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.非传染性仙台病毒载体编码 c-myc 抑制剂 FUSE 结合蛋白相互作用抑制剂联合顺铂治疗恶性胸膜间皮瘤的协同作用。
Cancer Sci. 2011 Jul;102(7):1366-73. doi: 10.1111/j.1349-7006.2011.01931.x. Epub 2011 May 9.
5
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.阻断 ERK1 和 ERK2 可使人类间皮瘤细胞对多柔比星敏感。
Mol Cancer. 2010 Dec 15;9:314. doi: 10.1186/1476-4598-9-314.